Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631 (Leukemia, (2021), 35, 5, (1279-1290), 10.1038/s41375-021-01177-6)

Patrick A. Brown, John A. Kairalla, Joanne M. Hilden, Zo Ann E. Dreyer, Andrew J. Carroll, Nyla A. Heerema, Cindy Wang, Meenakshi Devidas, Lia Gore, Wanda L. Salzer, Naomi J. Winick, William L. Carroll, Elizabeth A. Raetz, Michael J. Borowitz, Donald Small, Mignon L. Loh, Stephen P. Hunger

Research output: Contribution to journalComment/debatepeer-review

Abstract

Figure 3 of the original article was an incorrect version. The correct figure is: The original article has been updated. (Figure presented.).

Original languageEnglish (US)
Pages (from-to)1527
Number of pages1
JournalLeukemia
Volume35
Issue number5
DOIs
StatePublished - May 2021
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631 (Leukemia, (2021), 35, 5, (1279-1290), 10.1038/s41375-021-01177-6)'. Together they form a unique fingerprint.

Cite this